Caliway Announces Successful EOP2 Meeting with FDA for CBL-514
Caliway Biopharmaceuticals (TWSE: 6919) today announced the successful End-of-Phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) for CBL-514, the company’s proprietary...